SOUTH SAN FRANCISCO, Calif., Nov. 1, 2017 /PRNewswire/ -- Perlara, a drug discovery platform company partnering with highly motivated families and drug developers to cure diseases thought too rare to matter, today announced the closing of a $7.4M round of equity financing with participation by Pivotal Capital Alpha, Al-Hamra Group, Radical Investments, Homebrew Ventures, Haystack Fund and existing investors, including Y Combinator. Novartis participated in the financing under the terms of its research collaboration with Perlara.
The company has raised a total of $9.9M since inception in 2014.
"With this funding we will be able to advance programs forward, discover novel lead compounds for our first three PerlQuest partners, and double our disease pipeline with the launch of six new PerlQuests," says Perlara founder and CEO Ethan Perlstein, PhD.
About Perlara Perlara is a public benefit corporation working to develop cures for rare diseases and learn how genes work across diseases to map connections to common ailments. For general information and updates, please visit us at perlara.com, connect with us at @PerlaraPBC on Twitter and at www.facebook.com/PerlaraPBC on Facebook, and learn specifically about PerlQuests at www.perlara.com/perlquests and www.perlara.com/faqs.
ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint's commercial growth and success over...
With a goal to better inform health care workers about weapons of mass destruction, the Emergency Nurses Association and FBI recently partnered to launch the Bureau's "ABCs on WMDs" podcast series on the association's website....
Emperion is proud to announce the appointment of Matt Padden as the newest addition to its leadership team. With a proven track record of driving sales growth and cultivating strong client relationships, Padden brings a wealth of experience and...
Validation Institute announced finalists for its seventh annual Health Value Awards, which recognize outstanding services, products, and programs spanning healthcare. The awards also highlight employers and solution providers that have implemented...
Today, Cyclopure announced the inclusion of its PFAS Water Test Kit in a pilot program being conducted by the Colorado Department of Public Health and Environment (CDPHE). CDPHE is piloting the program called the "PFAS Testing and Assistance Program"...
Balance Point Capital Advisors, LLC ("Balance Point"), in conjunction with its affiliated fund, Balance Point Capital Partners V, L.P., is pleased to announce its follow-on investment in Supreme Group ("Supreme" or the "Company"), a portfolio company...
